First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part,
first-in-human study to assess the safety and tolerability of CCW702 administered
subcutaneously to patients with metastatic, castration resistant prostate cancer. In part I,
patients will receive ascending dosages of CCW702 with the goal to determine the maximum
tolerated dose (MTD) of CCW702. In part II of the study, patients will be given the
recommended phase 2 dose (RP2D) evaluating two regimens of CCW702 to determine which regimen
is most efficacious. The study will also assess the pharmacokinetics and pharmacodynamics of
CCW702.